Young HIV-positive male patient with severe atopic dermatitis on dupilumab and SARS-CoV-2 infection, a pioneer hypothesis.
作者信息
Ordóñez-Rubiano María F, Rubiano-Mojica Paula C, Casas Mirian
机构信息
Department of Dermatology, Cayre Clinical Center, Atopic Dermatitis Clinic, Bogotá, Colombia.
Division of Dermatology, Department of Internal Medicine, Military Central Hospital, Bogotá, Colombia.
出版信息
Int J Dermatol. 2021 Apr;60(4):514-515. doi: 10.1111/ijd.15499. Epub 2021 Feb 28.
Abstract
摘要
相似文献
1
Young HIV-positive male patient with severe atopic dermatitis on dupilumab and SARS-CoV-2 infection, a pioneer hypothesis.一名感染严重特应性皮炎的HIV阳性年轻男性患者使用度普利尤单抗及感染了SARS-CoV-2，一个初步假设。
Int J Dermatol. 2021 Apr;60(4):514-515. doi: 10.1111/ijd.15499. Epub 2021 Feb 28.
2
Allergic contact dermatitis to Compositae: A possible cause of dupilumab-associated facial and neck dermatitis in atopic dermatitis patients?对菊科植物的过敏性接触性皮炎：特应性皮炎患者中 dupilumab 相关面部和颈部皮炎的一个可能原因？
Contact Dermatitis. 2021 Oct;85(4):473-474. doi: 10.1111/cod.13898. Epub 2021 May 27.
3
Two Cancer Patients Receiving Dupilumab for Treatment of Atopic Dermatitis.两名接受度普利尤单抗治疗特应性皮炎的癌症患者。
Acta Derm Venereol. 2019 Sep 1;99(10):899-900. doi: 10.2340/00015555-3201.
4
Alopecia Universalis and Atopic Dermatitis Improvement with Dupilumab: Demonstration of a Shared Pathophysiology and Clinical Efficacy.度普利尤单抗改善全秃和特应性皮炎：共同病理生理学及临床疗效的证明
Skinmed. 2019 May 29;17(2):139-140. eCollection 2019.
5
EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers.湿疹面积和严重程度指数（EASI）与改良湿疹面积和严重程度指数（p-EASI）：使用血清生物标志物组合预测接受度普利尤单抗治疗的特应性皮炎患者的疾病严重程度
Allergy. 2020 Dec;75(12):3287-3289. doi: 10.1111/all.14492. Epub 2020 Jul 24.
6
Safe and effective treatment of atopic dermatitis using dupilumab over 23 months in a patient with HIV.在一名 HIV 患者中，使用度普利尤单抗治疗 23 个月，安全且有效治疗特应性皮炎。
Dermatol Ther. 2020 Nov;33(6):e14271. doi: 10.1111/dth.14271. Epub 2020 Sep 14.
7
Dupixent® (Dupilumab): A Newly Approved Interleukin-4 Receptor Antagonist for the Treatment of Atopic Dermatitis in Pediatric Patients.度普利尤单抗（Dupixent®）：一种新获批用于治疗儿童特应性皮炎的白细胞介素-4受体拮抗剂。
Skinmed. 2019 May 29;17(2):107-109. eCollection 2019.
8
Safety and efficacy of dupilumab in a patient with severe atopic dermatitis and HIV infection, with 15 months of follow-up.
Clin Exp Dermatol. 2020 Aug;45(6):762-763. doi: 10.1111/ced.14278. Epub 2020 Jun 13.
9
Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2.度普利尤单抗可改善中重度特应性皮炎患者的报告症状、焦虑和抑郁症状以及健康相关生活质量：来自随机试验 SOLO 1 和 SOLO 2 的汇总数据分析。
J Dermatolog Treat. 2020 Sep;31(6):606-614. doi: 10.1080/09546634.2019.1612836. Epub 2019 Jun 9.
10
Dupilumab in atopic dermatitis, a protocol for SARS-COV-2-infected patients.度普利尤单抗治疗特应性皮炎：SARS-CoV-2感染患者的方案
Dermatol Ther. 2020 Nov;33(6):e14172. doi: 10.1111/dth.14172. Epub 2020 Sep 5.
引用本文的文献
1
Targeted Systemic Therapies for Adults with Atopic Dermatitis: Selecting from Biologics and JAK Inhibitors.成人特应性皮炎的靶向全身治疗：从生物制剂和JAK抑制剂中进行选择。
Am J Clin Dermatol. 2024 Mar;25(2):179-193. doi: 10.1007/s40257-023-00837-w. Epub 2024 Jan 12.
2
Impact of Anti-Type 2 Inflammation Biologic Therapy on COVID-19 Clinical Course and Outcome.抗2型炎症生物疗法对COVID-19临床病程及结局的影响
J Inflamm Res. 2021 Dec 14;14:6845-6853. doi: 10.2147/JIR.S345665. eCollection 2021.
3
Risk of COVID-19 and its complications in patients with atopic dermatitis undergoing dupilumab treatment-a population-based cohort study.患有特应性皮炎并接受度普利尤单抗治疗的患者罹患 COVID-19 及其并发症的风险：一项基于人群的队列研究。
Immunol Res. 2022 Feb;70(1):106-113. doi: 10.1007/s12026-021-09234-z. Epub 2021 Oct 13.
4
COVID-19 in Patients with Atopic Dermatitis Treated with Dupilumab: Three Cases and a Literature Review.使用度普利尤单抗治疗的特应性皮炎患者中的COVID-19：三例病例及文献综述
Clin Cosmet Investig Dermatol. 2021 Aug 27;14:1131-1138. doi: 10.2147/CCID.S321003. eCollection 2021.
本文引用的文献
1
Dupilumab in HIV-positive patients: A case series report of 4 patients.度普利尤单抗治疗HIV阳性患者：4例病例系列报告
JAAD Case Rep. 2020 Oct 9;6(12):1356-1359. doi: 10.1016/j.jdcr.2020.09.023. eCollection 2020 Dec.
2
Dupilumab in atopic dermatitis, a protocol for SARS-COV-2-infected patients.度普利尤单抗治疗特应性皮炎：SARS-CoV-2感染患者的方案
Dermatol Ther. 2020 Nov;33(6):e14172. doi: 10.1111/dth.14172. Epub 2020 Sep 5.
3
Coronavirus disease 2019 (COVID-19) outcomes in HIV/AIDS patients: a systematic review.新型冠状病毒病 2019（COVID-19）在艾滋病毒/艾滋病患者中的结局：一项系统评价。
HIV Med. 2020 Oct;21(9):567-577. doi: 10.1111/hiv.12911. Epub 2020 Jul 15.
4
European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection and atopic dermatitis.欧洲特应性皮炎工作组关于严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染与特应性皮炎的声明。
J Eur Acad Dermatol Venereol. 2020 Jun;34(6):e241-e242. doi: 10.1111/jdv.16411.
5
Reconstitution of Peripheral T Cells by Tissue-Derived CCR4+ Central Memory Cells Following HIV-1 Antiretroviral Therapy.HIV-1抗逆转录病毒治疗后组织来源的CCR4+中央记忆细胞对外周T细胞的重建
Pathog Immun. 2016;1(2):260-290. doi: 10.20411/pai.v1i2.129.
Zotero 插件